Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKesson
Johnson and Johnson
Mallinckrodt
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,168,758

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,168,758
Title:Anti-MN antibodies and methods of using same
Abstract: The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.
Inventor(s): Tamburini; Paul (Kensington, CT), Ranges; Gerald (Hamden, CT), Adnane; Lila (Pine Brook, NJ), Mccabe; Timothy (Doylestown, PA), Trail; Pamela (Madison, CT), Ha; Sha (Blue Bell, PA)
Assignee: Bayer HealthCare LLC (Tarrytown, NY)
Application Number:12/086,320
Patent Claims:1. An antibody or antibody fragment having an antigenic binding site specifically directed against an MN protein, wherein the antigenic binding site of said antibody or antibody fragment comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOs: 57, 63, and 70 and a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOs: 89, 93, and 97.

2. The antibody or antibody fragment according to claim 1, wherein the antibody or antibody fragment binds to the MN protein with a dissociation constant of about 0.15 nM to about 50 nM.

3. The antibody or antibody fragment according to claim 1, wherein the antibody is an IgG.

4. The antibody or antibody fragment according to claim 1, wherein the antibody is an IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA, IgM Fab fragment, F(ab')2 fragment, scFv fragment, Fv fragment, a diabody, linear antibody, single-chain antibody, bispecific antibody, chimeric antibody, or multispecific antibody.

5. The antibody or antibody fragment according to claim 1, wherein the antibody or antibody fragment is humanized.

6. A composition comprising an antibody or antibody fragment thereof according to claim 1 and one or more pharmaceutical auxiliary substances.

7. A composition reactive against MN protein comprising an antibody or antibody fragment having an antigenic binding site specifically directed against an MN protein conjugated to one or more cytotoxic agents, wherein the antigenic binding site of said antibody or antibody fragment comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOs: 57, 63, and 70 and a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOs: 89, 93, and 97.

8. The composition according to claim 7, wherein the one or more cytotoxic agents is selected from the group consisting of: monomethylauristatin-E, monomethylauristatin-F, aplidin, azaribine, anastrozole, azacytidine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, cisplatin, irinotecan (CPT-11), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3',5'--O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, PSI-341, semustine streptozocin, tamoxifen, taxanes, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, velcade, vinblastine, vinorelbine, vincristine, ricin, abrin, ribonuclease, onconase, rapLR1, DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.

9. The composition according to claim 7, wherein one of the cytotoxic agents is monomethylauristatin-E.

10. The composition according to claim 7, wherein the antibody or antibody fragment binds to the MN protein with a dissociation constant of about 0.15 nM to about 50 nM.

11. The composition according to claim 7, wherein the antibody is an IgG.

12. The antibody or antibody fragment according to claim 7, wherein the antibody is an IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA, IgM Fab fragment, F(ab')2 fragment, scFv fragment, Fv fragment, a diabody, linear antibody, single-chain antibody, bispecific antibody, chimeric antibody, or multispecific antibody.

13. The antibody or antibody fragment according to claim 7, wherein the antibody or antibody fragment is humanized.

14. A composition for treating a subject having an MN-expressing cancer, said composition comprising an anti-cancer agent and an antibody or antibody fragment thereof having an antigenic binding site specifically directed against an MN protein coniugated to a cytotoxic agent, wherein the antigenic binding site of said antibody or antibody fragment comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOs: 57, 63, and 70 and a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOs: 89, 93, and 97.

15. The composition according to claim 14, wherein the anti-cancer agent is selected from the group consisting of: capecitabine, bleomycin, docetaxel (Taxotere.TM.), doxorubicin, edatrexate, erlotinib (Tarceva.TM.), etoposide, finasteride (Proscar.TM.), flutamide (Eulexin), gemcitabine (Gemzar.TM.), genitinib (Irresa), goserelin acetate (Zoladex.TM.), granisetron (Kytril.TM.), imatinib (Gleevec.TM.), irinotecan (Campto/Camptosar.TM.), ondansetron (Zofran.TM.), paclitaxel (Taxol.TM.), pegaspargase (Oncaspar.TM.), pilocarpine hydrochloride (Salagen.TM.), porfimer sodium (Photofrin.TM.), interleukin-2 (Proleukin.TM.), rituximab (Rituxan.TM.), topotecan (Hycamtin.TM.), trastuzumab (Herceptin.TM.), Triapine.TM., vincristine, vinorelbine tartrate (Navelbine.TM.), and therapeutic antibodies or fragments thereof.

16. The composition according to claim 14, wherein the anti-cancer agent is an anti-angiogenic agent selected from the group consisting of angiostatin, bevacizumab (Avastin.RTM.), sorafenib (Nexavar.RTM.), baculostatin, canstatin, maspin, anti-VEGF antibodies or peptides, anti-placental growth factor antibodies or peptides, anti-Flk-1 antibodies, anti-Fit-1 antibodies or peptides, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, IP-10, Gro-13, thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, CM101, Marimastat, pentosan polysulphate, angiopoietin 2, interferon-alpha, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 and minocycline.

17. The composition according to claim 14, wherein the anti-cancer agent is an agent that blocks or inhibits a multi-drug resistance phenotype selected from the group consisting of tamoxifen, verapamil and cyclosporin A.

18. The composition according to claim 14, wherein the cytotoxic agent is monomethylauristatin-E.

19. The composition according to claim 14, wherein the antibody or antibody fragment binds to the MN protein with a dissociation constant of about 0.15 nM to about 50 nM.

20. The composition according to claim 14, wherein the antibody is an IgG.

21. The composition according to claim 14, wherein the antibody is an IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA, IgM Fab fragment, F(ab')2 fragment, scFv fragment, Fv fragment, a diabody, linear antibody, single-chain antibody, bispecific antibody, chimeric antibody, or multispecific antibody.

22. The composition according to claim 14, wherein the antibody or antibody fragment is humanized.

23. The composition according to claim 14, wherein the cancer is in the form of a solid tumor.

24. The composition according to claim 23, wherein the solid tumor is in or originating from the breast, respiratory tract, lung, brain, reproductive organ, digestive tract, colon, urinary tract, kidney, esophagus, cervix, eye, liver, skin, head, neck, thyroid, or parathyroid.

25. A kit comprising the antibody or antibody fragment according to claim 1 and a set of instructions for using the kit.

26. A kit comprising the composition according to claim 7 and a set of instructions for using the kit.

27. A kit comprising the composition according to claim 14 and a set of instructions for using the kit.

28. An antibody or antibody fragment having an antigenic binding site specifically directed against an MN protein, wherein the antigenic binding site of said antibody or antibody fragment comprises a heavy chain variable region comprising SEQ ID NO:145 and a light chain variable region comprising SEQ ID NO:146.

29. An anti-MN IgG antibody encoded by the nucleotide sequence of SEQ ID NO: 153, wherein said antibody comprises a heavy chain variable region comprising SEQ ID NO: 145 and a light chain variable region comprising SEQ ID NO: 146.

Summary for Patent:   Start Trial

PCT Information
PCT FiledDecember 12, 2006PCT Application Number:PCT/US2006/047445
PCT Publication Date:June 21, 2007PCT Publication Number:WO2007/070538

Details for Patent 8,168,758

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Bayer HealthCare LLC (Tarrytown, NY) 2025-12-12 RX search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial Bayer HealthCare LLC (Tarrytown, NY) 2025-12-12 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Bayer HealthCare LLC (Tarrytown, NY) 2025-12-12 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Bayer HealthCare LLC (Tarrytown, NY) 2025-12-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Bayer HealthCare LLC (Tarrytown, NY) 2025-12-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Medtronic
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.